Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.GRCE · Entity 7266 | Director | September 17, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.13 · Expires 2036-09-16 | Direct | 12,200 |
Reported balance
After 2026-09-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-17 · Grant · Acquired 12,200 · Balance 12,200 F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 20:15 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 12,200 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001140361-26-037239 · form4.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,200 Underlying: Common Stock · 12,200 shares Expires 2036-09-16 F1 · derivative.exercise_date: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 21:01 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001140361-26-000969 · form4.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: 25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:21 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001140361-25-018694 · form4.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-09 F1 · derivative.exercise_date: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2025, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 21:08 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0000950170-23-071885 · ownership.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Shares · 10,000 shares Expires 2033-12-19 F1 · derivative.exercise_date: Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which vest in equal monthly installments over a period of 12 months, provided that 3/12 of the options shall be deemed to have vested upon the date of grant. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 23:46 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | PurchaseCommon Warrants (right to buy) · Derivative | 422,732 | $0.13 Strike: $3.00 | $52,841.50 |
DisclosureSEC source: 0001062993-23-018542 · form4.xml · derivative · entry 3 Kavuru Vimal · CIK 0001697184 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 422,732 Underlying: Common Shares · 422,732 shares Expires not disclosed F4 · derivative.exercise_date: The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder and certain other related parties, would not beneficially own after any such exercise more than 19.99% of the then issued and outstanding common shares of the Company (the "Blocker"). Due to the Blocker, the Common Warrants beneficially owned indirectly by the holder are only currently partially exercisable. F5 · derivative.expiration_date: The Common Warrants will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) September 25, 2028. F2 · ownership.nature: These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member. Read SEC document |
| September 25, 2023 Filed Sep 27, 2023 23:46 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | PurchaseCommon Shares | 676,371 | $1.85 | $1,249,933.61 |
DisclosureSEC source: 0001062993-23-018542 · form4.xml · nonDerivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,188,076 F1 · balance_after: These indirect holdings have been adjusted to give effect to the Company's 1-for-6 reverse stock split, effective July 10, 2023. F2 · ownership.nature: These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:36 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001062993-23-014999 · form4.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Class A Common Shares · 12,500 shares Expires 2033-07-14 F1 · derivative.exercise_date: Stock options granted on 07/14/2023 under the Acasti Pharma Stock Option Plan, which vest and become exercisable in equal monthly installments over a period of 12 months. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:21 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001171843-22-006335 · ownership.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Shares · 45,000 shares Expires 2032-09-28 F1 · derivative.exercise_price: Based on conversion of exercise price of C$0.80 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7321 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 09/28/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 21:20 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 42,100 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001171843-21-008009 · ownership.xml · derivative · entry 1 Kavuru Vimal · CIK 0001697184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,100 Underlying: Class A Common Shares · 42,100 shares Expires 2031-11-12 F1 · derivative.exercise_price: Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable with respect to 25% of the shares every three months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.